insights_auto
Why is ADAPY down 24.64%?
Dive Deeperchevron_right
ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
$0.021
arrow_downward
-24.64%(-0.0069) 1D
Nov 13, 10:17:37 AM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ADAPY...
Open
$0.02
High
$0.03
Low
$0.02
Mkt. cap
5.22M
Avg. vol.
295.99K
Volume
88.53K
52-wk high
$0.07
52-wk low
$0.00
Beta
0.87
Shares outstanding
265.05M
No. of employees
272
Open
$0.02
High
$0.03
Low
$0.02
Mkt. cap
5.22M
Avg. vol.
295.99K
Volume
88.53K
52-wk high
$0.07
52-wk low
$0.00
Beta
0.87
Shares outstanding
265.05M
No. of employees
272
News stories
From web sources and news partners
Reuters
·
1 hour ago
Goldman Sachs sees S&P 500 rising to 8,700 next year despite slower earnings growth
Investopedia
·
48 minutes ago
Stock Market Today: S&P 500, Nasdaq Slip in Early Trading as Nvidia Shares Continue Falling; Major Indexes Remain on Track for Big Weekly Gains
Yahoo Finance
·
1 hour ago
Wall Street Divided on S&P 500: Which ETFs Could Benefit in 2027?
ChartMill
·
2 hours ago
S&P 500 Premarket Movers: Travelers, Palo Alto Networks Gain; Cisco, AMD Fall
Profile
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
About Adaptimmune Therapeutics PLC - ADR
CEOAdrian Rawcliffe
Employees272
Founded2008
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteadaptimmune.com